Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study

References

• Miranda-Filho A, Piñeros M, Znaor A, et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489–499.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018;24(6):1163–1171.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZS, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25(18):2554–2559.
   PubMed Web of Science ®Google Scholar
• Kothari J, Peggs KS, Bird A, et al. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Br J Haematol. 2014;165(3):334–340.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Phipps C, Gopal AK, Storer BE, et al. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Leuk Lymphoma. 2015;56(1):92–96.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182–190.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667.
   PubMed Web of Science ®Google Scholar
• Nigg EA. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature. 1997;386(6627):779–787.
   PubMed Web of Science ®Google Scholar
• Camus V, Miloudi H, Taly A, et al. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol. 2017;10(1):47.
   PubMedGoogle Scholar
• Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 2020;13(1):1–9.
   PubMed Web of Science ®Google Scholar
• Taylor J, Sendino M, Gorelick AN, et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov. 2019;9(10):1452–1467.
   PubMed Web of Science ®Google Scholar
• Luo B, Huang L, Gu Y, et al. Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. Int J Clin Exp Pathol. 2018;11(12):5547–5560.
   PubMed Web of Science ®Google Scholar
• Culjkovic-Kraljacic B, Baguet A, Volpon L, et al. The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep. 2012;2(2):207–215.
   PubMed Web of Science ®Google Scholar
• Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 2007;17(4):193–201.
   PubMed Web of Science ®Google Scholar
• Topisirovic I, Siddiqui N, Borden KLB. The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes. Cell Cycle. 2009;8(7):960–961.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Senapedis W, McCauley D, et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85.
   PubMed Web of Science ®Google Scholar
• Tan DSP, Bedard PL, Kuruvilla J, et al. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov. 2014;4(5):527–537.
   PubMed Web of Science ®Google Scholar
• Azmi AS, Al-Katib A, Aboukameel A, et al. Selective inhibitors of nuclear export for the treatment of non-Hodgkin’s lymphomas. Haematologica. 2013;98(7):1098–1106.
   PubMed Web of Science ®Google Scholar
• Marullo R, Yang S, Rashal T, et al. Abstract LB-062: XPO1 is a rational target for double and triple-hit aggressive B-cell lymphomas. Cancer Res. 2015;75:LB-062.
   Web of Science ®Google Scholar
• Crespo M, Carabia J, Jiménez I, et al. XPO1 inhibition by selinexor synergizes with BCR inhibition, blocks tumor growth and prolongs survival in a bioluminescent animal model of primary central nervous system lymphoma. Blood. 2016;128(22):463.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621–4634.
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Ishizawa J, Ruvolo V, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014;105(7):795–801.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129(24):3175–3183.
   PubMed Web of Science ®Google Scholar
• Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511–e522.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988.
   PubMed Web of Science ®Google Scholar